Esperion Therapeutics Inc. (ESPR) Stock Rating Lowered by Zacks Investment Research
Esperion Therapeutics Inc. (NASDAQ:ESPR) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Monday.
According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
ESPR has been the topic of a number of other research reports. Barclays PLC set a $13.00 target price on shares of Esperion Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 31st. Stifel Nicolaus reiterated a “buy” rating and set a $64.00 price target on shares of Esperion Therapeutics in a research report on Thursday, September 22nd. Vetr lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 price target on the stock. in a research report on Tuesday, August 23rd. Credit Suisse Group AG reiterated a “sell” rating and set a $10.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, July 6th. Finally, Royal Bank Of Canada lowered shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $30.00 to $15.00 in a research report on Wednesday, June 29th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $26.36.
Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at 12.38 on Monday. Esperion Therapeutics has a 12 month low of $9.58 and a 12 month high of $30.41. The firm’s 50 day moving average is $12.43 and its 200 day moving average is $13.85. The company’s market cap is $279.17 million.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. During the same quarter last year, the business posted ($0.55) EPS. On average, equities analysts predict that Esperion Therapeutics will post ($3.37) earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in ESPR. Quantitative Investment Management LLC acquired a new position in Esperion Therapeutics during the second quarter valued at about $111,000. Advisor Group Inc. acquired a new position in Esperion Therapeutics during the second quarter valued at about $140,000. Stifel Financial Corp increased its position in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 1,438 shares during the last quarter. Rhumbline Advisers increased its position in Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 3,657 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 238 shares during the last quarter. 65.23% of the stock is owned by hedge funds and other institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.